A recent study suggests that individuals who stop using blockbuster slimming jabs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle plans.
Research printed in a leading medical journal shows that while obese individuals can lose a large proportion of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing such medications must be aware of the potential of quick rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.
Such speed of regain implies a reversion to pre-treatment weight in about 18 months.
Analyzing Treatments
The study, which reviewed 37 of trials involving thousands of patients, compared the effects of GLP-1 agonists with older methods.
Researchers note that people who shed pounds through lifestyle changes alone generally experience a more gradual weight regain—approximately 100 grams monthly—after stopping.
The Reason for the Rapid Regain
Doctors propose the way of the drugs is key to understanding the amplified rebound.
These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and may also lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication results in hunger is no longer kept in check, making overeating a significant risk."
A Lifelong Disease?
Health authorities recommend the jabs for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals argue that, considering the high risk of weight regain, the treatment is often life-long.
This view is echoed by pharmaceutical companies, who say that the results "emphasize the chronic nature of obesity," comparing it to managing conditions like hypertension.
Patient Testimonies
Users who have come off the medication report a intense return of hunger.
"It felt as if something that goes on and you're instantly starving," said an individual.
This challenge is compounded if users have not established lasting lifestyle or habit changes during treatment.
Growing Interest
Survey data show that millions of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and maintained weight loss relies on integrated lifestyle management.